skip to Main Content

Rheumatoid Arthritis Drugs Market is expected to increase to US$ 49.86 Billion by 2030

In a report named ” Rheumatoid Arthritis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2030,” issued recently by Renub Research, market share insights are incorporated along with a detailed industry analysis. The analysis of competitors, topographical regions, and growth for rheumatoid arthritis drugs market is also enclosed in the report.

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures:

Rheumatoid Arthritis Drugs Market will increase at a CAGR of 4.72%, between 2022 and 2030. Presently, there is no cure for Rheumatoid Arthritis, but there are treatments that can help control the symptoms and prevent joint damage. Treatment covers medication, lifestyle changes, and physical therapy. Rheumatoid arthritis drugs are medications used to treat rheumatoid arthritis, a chronic inflammatory disease that influence the joints. These medications suppress the immune system and reduce inflammation. There are numerous types of rheumatoid arthritis drugs available, including biologics, conventional synthetic DMARDs, small-molecule DMARDs, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs.

The escalating prevalence of RA on a global scale, driven by aging populations and lifestyle changes, fuels the demand for effective treatments. According to the World Health Organization (WHO), an estimated 18 million people worldwide were living with rheumatoid arthritis (RA). This is about 0.46% of the global population. RA is more common in women than in men, with about 70% of people with RA being women. This burgeoning patient pool necessitates innovative drug solutions to alleviate symptoms, halt disease progression, and improve patients’ quality of life. Rheumatoid Arthritis Drugs market will value about US$49.86 Billion by 2030 due to rising disease prevalence, advances in treatment options, and increasing patient awareness and access to innovative therapies.

Furthermore, rising patient awareness of rheumatic disorders and the introduction of new biopharmaceuticals globally are expected to boost rheumatoid arthritis (RA) therapeutic adoption. Most patients who have received Disease-Modifying Antirheumatic Drugs (DMARDs) remain dissatisfied due to inadequate therapeutic benefits. A combination of biologics and DMARDs is likely to provide greater therapeutic benefits for this patient group. As a result, the rheumatoid arthritis market is shifting toward combination therapies that improve patient outcomes. The growing probe of DMARD/biologic combinations will boost market revenue in the future.

Injectable therapies for rheumatoid arthritis (RA) are presently dominating the market.

These therapies, including biologic drugs and disease-modifying antirheumatic drugs (DMARDs), offer direct delivery to the affected joints, resulting in faster symptom relief and reduced disease progression. Injectable treatments also provide a longer duration of action, requiring fewer administrations compared to oral medications. Thus, they enhance patient compliance and improve therapeutic outcomes, making injectable therapies the preferred choice for RA management.

Request a free sample copy of the report:

Product Types – Rheumatoid Arthritis Drugs Market has been covered from 3 viewpoints.

1.    Oral

2.    Parenteral

3.    Tropical

Biopharmaceuticals lead the rheumatoid arthritis treatment industry due to their targeted mechanism, addressing underlying causes of the disease.

Biologics and biosimilars, among other advanced therapies, provide personalized treatment options with fewer side effects. They effectively suppress inflammation and slow the progression of disease, resulting in better patient outcomes. This precision and efficacy make biopharmaceuticals the first choice for managing rheumatoid arthritis.

Therapeutic Molecules – Rheumatoid Arthritis Drugs Market has been covered from 2 viewpoints.

1.    Pharmaceuticals

2.    Bio-pharmaceuticals

Pharmaceutical analgesics are experiencing rapid growth in the rheumatoid arthritis treatment market.

As patients seek comprehensive relief from RA symptoms, analgesics offer immediate relief, enhancing their quality of life. The market expansion is further driven by the development of novel analgesic formulations that provide targeted pain management while minimizing adverse effects. With a growing emphasis on improving patient comfort and well-being, pharmaceutical analgesics have become integral to the multidimensional approach in treating rheumatoid arthritis.

Pharmaceuticals – Rheumatoid Arthritis Drugs Market has been covered from 7 viewpoints.

1.    Disease-modifying Anti-rheumatic Drugs (DMARDs)

2.    Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

3.    Corticosteroids

4.    Uric Acid Drugs

5.    Analgesics

6.    Anti-tumour necrosis factor (TNF)

7.    Others

With the growing focus on affordable yet effective therapies, biosimilars have emerged as a pivotal choice for rheumatoid arthritis management.

Biosimilars dominate the rheumatoid arthritis drug market with the highest share due to their cost-effectiveness and comparability to established biologics. Offering similar efficacy and safety profiles at reduced prices, biosimilars enhance patient access to essential treatments. Regulatory approvals and endorsements by healthcare organizations have bolstered their credibility, fostering wider adoption.

Bio-Pharmaceuticals – Rheumatoid Arthritis Drugs Market has been covered from 3 viewpoints.

1.    Bio-pharmaceuticals

2.    Biologics

3.    Biosimilars

Steroid surgery is witnessing an increase in the rheumatoid arthritis drugs market due to its targeted and rapid anti-inflammatory effects.

In cases of acute flares or localized joint pain, intra-articular steroid injections offer swift relief, reducing inflammation and alleviating discomfort. These procedures are minimally invasive and can provide significant symptom improvement, making them a valuable adjunct to the overall treatment regimen. Steroid surgery is becoming more popular in the rheumatoid arthritis drug market as pati

ents and healthcare providers seek immediate pain relief and inflammation control.

Surgery – Rheumatoid Arthritis Drugs Market has been covered from 3 viewpoints.

1.    Nonsteroidal Anti-inflammatory Drug Type

2.    Steroids

3.    Biologic Agents

As personalized medicine gains prominence, prescription sales channels will continue to hold sway in delivering safe, effective, and optimized rheumatoid arthritis drug regimens.

Prescription sales channels are set to dominate the rheumatoid arthritis drug market due to the complexity and critical nature of these medications. Rheumatoid arthritis treatments, often involving biologics and targeted therapies, require careful patient selection, dosing adjustments, and monitoring. Healthcare professionals play a vital role in prescribing and guiding patients through these therapies, necessitating controlled distribution and adherence. Moreover, the expertise of physicians ensures tailored treatment plans that align with patients’ unique medical profiles.

Sales Channel – Rheumatoid Arthritis Drugs Market has been covered from 2 viewpoints.

1.    Over-the-counter (OTC)

2.    Prescription

Online distribution channels are poised for substantial growth in the future of the rheumatoid arthritis drug market.

With the rise of digital healthcare and patient convenience, online platforms offer accessible information, prescription services, and medication delivery. This trend aligns with evolving patient preferences and the need for efficient access to treatments. They are expected to play a critical role in improving the distribution and accessibility of rheumatoid arthritis drugs as technology continues to reshape healthcare delivery.

Distribution Channel – Rheumatoid Arthritis Drugs Market has been covered from 3 viewpoints.

1.    Hospital Pharmacies

2.    Retail Pharmacies

3.    Online

As the focus on improving patient outcomes persists, North America is expected to retain its significant share in the rheumatoid arthritis drug market.

The North America region has high prevalence of rheumatoid arthritis, coupled with a well-developed healthcare infrastructure and robust research capabilities, fosters continuous advancements in treatment options. Favorable reimbursement policies and access to innovative therapies contribute to sustained market growth. Furthermore, increasing awareness among healthcare professionals and patients about early intervention and personalized treatment approaches strengthens the demand for these drugs.

Region – Rheumatoid Arthritis Drugs Market has been covered from 5 viewpoints.

1.    North America

2.    South America

3.    Europe

4.    Asia-Pacific

5.    Rest of World

The United States is poised for substantial growth in the rheumatoid arthritis treatment market due to its advanced healthcare landscape and high disease prevalence.

With a robust pharmaceutical industry, the U.S. is at the forefront of developing and adopting novel therapies, including biologics and targeted treatments. An aging population and increasing awareness of early intervention further drive demand. The availability of advanced diagnostic tools, coupled with favorable reimbursement policies, positions the U.S. to lead in rheumatoid arthritis treatment advancements.

Countries – Rheumatoid Arthritis Drugs Market has been covered from 22 perspectives.

1.    North America

1.1    United States

1.2    Canada

1.3    Mexico

2.    Europe

2.1    United Kingdom

2.2    Germany

2.3    France

2.4    Russia

2.5    Italy

2.6    Spain

2.7    Switzerland

3.    Asia-Pacific

3.1    India

3.2    China

3.3    Japan

3.4    Australia

3.5    South Korea

3.6    Indonesia

4.    Middle East & Africa

4.1    Saudi Arabia

4.2    United Arab Emirates

4.3    South Africa

5.    South America

5.1    Argentina

5.2    Brazil

5.3    Other Countries

6.    Rest of World

Competitive Landscape.

Eli Lilly and Co., Fibrogen Inc., Biogen Inc., Merck & Co. Inc., Abbvie Inc., Roche Holding AG, Novartis AG, and Johnson & Johnson are among the top competitors in the rheumatoid arthritis drug market.

Company Insights.

•    Overview

•    Recent Development

•    Revenue

Company Analysis.

1.    Eli Lilly and Co.

2.    Fibrogen Inc.

3.    Biogen Inc.

4.    Merck & Co. Inc

5.    Abbvie Inc.

6.    Roche Holding AG

7.    Novartis AG

8.    Johnson & Johnson

Related Reports


Wound Care Market:

Multiple Myeloma Market:

Prostate Cancer Diagnostics Market:

Lung Cancer Screening Market:

Diabetes Drugs Market:

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076



This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top